Flu Hospitalization Rate Week 18: Market Locks In

CDC FluView has been the quiet engine behind this market all season. The 85-90 cumulative hospitalization rate range for Week 18, 2026 now commands a 94% implied probability, and the price has barely flinched in 30 days. The market has already decided. The question worth asking is whether the underlying surveillance data gives traders any reason to revisit that call before the May 15 resolution date.

Here’s what the measurements are telling us: the 2025-2026 influenza season followed a familiar arc. Hospitalizations peaked in late winter and have been declining through April. By Week 18, which covers the period ending approximately May 2, 2026, cumulative hospitalization rates tracked by CDC’s FluSurv-NET network typically settle well below the winter peak. The 85-90 range per 100,000 population reflects a season that was active but not historically severe. Traders have priced that read at near-certainty.

How the Flu Hospitalization Week 18 Contract Works

This contract resolves YES if CDC FluView reports a cumulative influenza-associated hospitalization rate in the 85-90 range per 100,000 population for Week 18 of the 2026 surveillance season. The Centers for Disease Control and Prevention, specifically its FluSurv-NET laboratory-confirmed hospitalization network, is the authoritative data source. Resolution is set for May 15, 2026, which gives CDC time to publish the Week 18 report before the deadline.

• YES (85-90 range): $0.94 per share, 94% implied probability. The contract pays if CDC Week 18 cumulative hospitalization sits between 85 and 90 per 100,000.
• NO (any other range): $0.06 per share, 6% implied probability. This covers outcomes below 80, 80-85, 90-95, 95-100, and 100-plus.

The NO outcome requires CDC FluSurv-NET to report a Week 18 cumulative hospitalization rate outside the 85-90 band. That means either a sharper-than-expected late-season decline pushing the figure below 85, or an unexpected resurgence carrying the rate above 90. Both scenarios demand a meaningful deviation from current surveillance trends. CDC FluView data revisions are possible but historically minor at this stage of the season.

Momentum and Market Signals

Sponsored Partner

The momentum composite here reads as near-stillness: no price movement in the last hour, a marginal 0.5% slip over 24 hours, and a trend score of 24.04. Combined, those three signals describe a market that has absorbed all available information and stopped moving. The most likely driver of that 24-hour dip is routine end-of-week position trimming, not a fresh data signal from CDC.

Total market volume sits at $1,993, with $1,241 trading in the last 24 hours and $9,988 in available liquidity. This is a thin market. At this volume level, a single large order can move the price noticeably. The liquidity figure of $9,988 represents order book depth, not trading activity. Traders should treat the 94% price as a market consensus reading, not a deep-pool certainty.

• 1h change: flat. No new CDC data dropped in the last hour. The market is at rest.
• 24h change: -0.5%. A minor slip, not a signal. No agency announcement or revised surveillance figure explains the move.
• Trend score: 24.04. Momentum is low and directionless. The contract is coasting toward resolution.
• Volume below $1M total. Thin liquidity means the 94% figure could reprice sharply if CDC publishes a surprising Week 18 cumulative rate before May 15.
• Related market signal: Measles U.S. 2026 at 100%. Other CDC-adjacent surveillance markets have resolved with high conviction this season, consistent with the pattern here.

Lines Analysis: What the CDC Data Favors

CDC FluSurv-NET cumulative hospitalization rates for the 2025-2026 season have tracked a moderate-to-active profile. By Week 18, the season’s cumulative burden typically reflects winter peaks that have already been counted. The 85-90 range is consistent with a season that saw meaningful hospitalization load but did not reach the extraordinary levels recorded in severe years like 2017-2018. That alignment between the market range and observed seasonal patterns is why traders have parked 94% of the probability there.

The primary risk to the 85-90 call is a CDC data revision or a late-season hospitalization uptick. A new influenza variant driving unexpected late-spring hospitalizations could push the cumulative rate above 90. Conversely, if preliminary Week 18 data came in lighter than expected, the rate could slip below 85. Neither scenario is well-supported by current surveillance trends, but CDC FluView does occasionally revise earlier weeks as additional laboratory reports arrive. Those revisions are small but not zero.

SIGNALS TO MONITOR:

• CDC FluView Week 18 publication (expected by May 9, 2026): the primary resolution trigger. Any reading outside 85-90 reprices this contract immediately.
• CDC FluSurv-NET data revisions for Weeks 15-17: late-arriving hospital reports can shift cumulative totals by one to three points.
• Influenza B or novel strain activity in late April and early May: a late-season surge would be the only plausible path to the 90-plus range.
• CDC Health Advisory Network alerts: any emergency communication about unusual late-season flu activity would be the clearest bearish signal available.
• State-level hospitalization reports from high-population states (California, Texas, New York): early indicators of whether national cumulative rates are tracking stable or shifting.

The $1,993 total volume reflects a market where most participants reached the same conclusion early and stopped trading. The data favors the 85-90 range. The only meaningful repricing event left is the CDC Week 18 publication itself, and the market has already priced the most likely outcome of that report.

LINES VERDICT

Season Lands in the Expected Band

The 2025-2026 flu season’s cumulative hospitalization trajectory points squarely at the 85-90 range for Week 18, and the CDC surveillance data has given traders no reason to look elsewhere. The data doesn’t care about the politics, and here the data has spoken clearly.

What the market says: At 94%, traders have effectively called this contract resolved. The only volatility risk before the May 15 deadline is a surprise in the CDC Week 18 FluView publication itself, which could produce a sharp price move given the thin $1,993 volume base.

Key unknown: The single most important event remaining is the CDC FluView Week 18 report. If the cumulative hospitalization rate prints outside the 85-90 band, this market reprices fast on very low liquidity.

Scientific Context

CDC FluSurv-NET has operated since 2003 as the United States’ primary laboratory-confirmed influenza hospitalization surveillance system. The network covers roughly 9% of the U.S. population across 13 states, and cumulative rates are extrapolated to national estimates. Week 18 data represents the full accumulated burden of a season from October through early May. Moderate seasons historically produce cumulative rates between 50 and 100 per 100,000. The 85-90 band sits in the upper portion of that moderate range, consistent with a season that generated real clinical burden without crossing into severe territory. Before May 15, the only events that would move this contract are the final Week 18 publication and any retrospective data revisions CDC applies to earlier surveillance weeks.

Frequently Asked Questions

• What does 94% probability mean for this contract? It means traders collectively place a 94% chance that CDC FluView reports a Week 18 cumulative influenza hospitalization rate between 85 and 90 per 100,000 population. Six percent remains on all other outcomes combined.
• What does the NO contract cover? NO pays out if CDC FluSurv-NET reports any Week 18 cumulative rate outside the 85-90 range, including below 80, 80-85, 90-95, 95-100, or 100-plus per 100,000 population.
• What single event could move this price before resolution? The CDC FluView Week 18 publication is the only remaining catalyst. A reading outside the 85-90 band would immediately reprice the contract, and thin volume means that move would be sharp.
• When does this market resolve? Resolution is set for May 15, 2026. CDC FluView Week 18 data is expected to be published before that deadline, providing the final data point for resolution.
• Is the $9,988 liquidity figure reliable? That figure represents order book depth, not trading activity. With only $1,993 in total volume, this is a thin market. Price can move disproportionately on a single large order.

This analysis reflects market conditions as of 2026-05-09 18:37:16. Prediction market probabilities are volatile and shift as new data and regulatory decisions emerge, especially as the 2026-05-15 00:00:00 resolution date approaches. Lines.com does not accept bets or provide financial or gambling advice. All market outcomes are uncertain.